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Abstract Oral rehydration solution (ORS) was established as
the cornerstone of therapy for dehydration secondary to acute
infectious diarrhea approximately 40 years ago. The efficacy of
ORS is based on the ability of glucose to stimulate Na and fluid
absorption in the small intestine via a cyclic AMP-independent
process. Despite the establishment that ORS is the primary
reason for the substantial reduction in morbidity and mortality
from diarrhea in children in developing countries, the use of
ORS has lagged for many reasons. This review highlights
efforts to establish a major reformulation of ORS following
the demonstration that short-chain fatty acids (SCFA) stimulate
colonic Na and fluid absorption by a cyclic AMP-independent
mechanism. The addition of high-amylose maize starch
(HAMS), a microbially-fermentable (or ‘resistant’) starch, to
ORS results in delivery of non-absorbed carbohydrate to the
colon where it is fermented to SCFA. To date, three randomized
controlled trials with a HAMS-ORS in south India have dem-
onstrated a substantial decrease in diarrhea duration in both
adults and children hospitalized for acute diarrhea. Significant
efforts are now underway to establish this dual-action, modified
HAMS-hypoosmolar ORS solution as the standard ORS for the
treatment of dehydration from acute diarrhea.
Keywords Acute diarrhea . Dual-action oral rehydration
solution . Fermentable/resistant starch . Oral rehydration
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Introduction
Oral rehydration solution (ORS) was originally developed in
the early 1970s to correct the substantial dehydration that
occurs as a result of severe diarrhea, especially acute infectious
diarrhea [1•, 2•, 3]. Though rehydration with intravenous (IV)
solutions has been employed for over a century, the logistics of
IV hydration with the need for sterile solutions are monumental
when hundreds and possibly thousands of individuals are af-
fected by large volume diarrhea (e.g., cholera) in developing
countries in field conditions with minimal medical resources,
including elemental sanitation and electricity. In its simplest
and original form, ORSwas an iso-osmolar, glucose-electrolyte
solution with added base (e.g., citrate in WHO-ORS) that was
designed to correct dehydration and metabolic acidosis [3].
Development of ORS
Three unrelated events during a 10-year period in 1960s and
1970s led to the development and employment of ORS in the
treatment of acute diarrhea. The initial scientific observations
that were critical to the subsequent development of ORS were
the establishment that glucose absorption in the mammalian
small intestine required luminal Na, and that Na absorption
was markedly enhanced by the presence of luminal glucose
(as well as luminal amino acids) [4]. Schultz and Zalusky
provided evidence for glucose-stimulated Na absorption and
Na-dependent glucose absorption in a series of experiments
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with in vitro rabbit ileum [5•]. Subsequent studies identified
the intestinal glucose-Na transporter as SGLT1 which has
been extensively studied by Wright and colleagues [6].
The second critical observation was the result of several
studies that established that: (1) cholera enterotoxin caused
diarrhea in clinical cholera by inducing fluid and electrolyte
secretion via activation of adenylate cyclase resulting in an
increase in cyclic AMP in intestinal epithelial cells [7]; and (2)
the action of cyclic AMP on intestinal epithelial transport
included both stimulation of active Cl secretion and inhibition
of electroneutral Na-Cl absorption (which represents the cou-
pling of parallel ion exchanges—Na-H and Cl-HCO3) [8].
However, most critical to the development of ORS was that
cholera enterotoxin (i.e., cyclic AMP) did not inhibit glucose-
stimulated Na and thus fluid absorption (Fig. 1). Thus, the
physiological basis of ORS rests on the demonstration that
absorptive and secretory processes in the mammalian small
intestine are separate and independent; that cholera-toxin-
mediated cyclic AMP-induced active Cl secretion does not
affect glucose-induced Na absorption; and conversely and
most important, glucose stimulates Na absorption via a cyclic
AMP-independent transport process (despite the stimulation
of active Cl secretion by cyclic AMP) [7–10]. In addition, it
was recently shown that glucose has an additional effect that
will increase Na and fluid absorption: glucose reverses cyclic
AMP’s down-regulation of Na-H exchanger 3 (NHE3) [11].
The third and most important event in the development and
rapid acceptance of ORS in the treatment of acute diarrhea
was its extensive and effective use under field conditions
during the Bangladeshi war of independence in the early
1970s [12]. The effective deployment of ORS in refugee
camps in Bengal demonstrated both its efficacy and effective-
ness to provide rehydration during acute diarrheal illnesses
that are self-limited (provided that the patient can be
successfully rehydrated). During this period, with an exten-
sive epidemic of cholera and other water-borne diarrheal
illnesses, the effective use of ORS under field conditions
established ORS as the mainstay of treatment for acute
diarrhea. Indeed, many have concluded that ORS was
the major therapeutic advance of the last (i.e., twentieth)
century [13]!
Modifications of WHO-ORS
Despite the great success of ORS in the treatment of acute
infectious diarrhea over the ensuing quarter century, there
have been several major efforts to modify the composition
of ORS with the goal to improve its efficacy (as demonstrated
in clinical trials) to reduce diarrhea (i.e., reduce both the time
to first formed stool and stool volume) and its effectiveness
(i.e., as established in field conditions). The use of one or more
amino acids, disaccharides, and polymers (e.g., sucrose)
added to ORS providedmodest but not dramatic improvement
in efficacy [14–19]. Major efforts have been made to employ
food-based, cereal-based ORS formulations [20–25]. The ini-
tial ORS formulation (often referred to as WHO-ORS) is
“isoosmolar” (i.e., 311 mOsm/kg H20). Since food-based
formulations result in hydrolysis of oligosaccharides and pep-
tides in the proximal small intestine, resulting in the release of
substantial amounts of amino acids and hexoses, these food-
based ORS formulations have, in general, been hypo-osmolar
(e.g., ~245 mOsm/kg H20). Several appropriately designed
randomized controlled trials have subsequently demonstrated
that such formulations are significantly better than WHO-
ORS (i.e., iso-osmolar) [23]. However, the question was
raised whether the improved efficacy of meal-based ORS
formulations was not due to the presence of food polymers
Fig. 1 Physiologic basis of
efficacy of oral rehydration
solution (ORS): electrolyte
absorption occurs in villous cells,
while secretion in crypt cells.
Increases in intracellular cAMP
inhibit Na-Cl absorption (that is
the result of parallel Na-H and Cl-
HCO3 exchanges) in villous cells
and stimulates active Cl and/or
HCO3 secretion in crypt cells. In
contrast, glucose-stimulated Na
absorption also in villous cells is
not affected by increases in
intracellular cAMP. Thus, the
glucose enhances Na and fluid
absorption despite persistence of
stimulation of Cl secretion and
inhibition of Na-Cl absorption
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per se but was a result of the hypo-osmolality of these formu-
lations [26]. As a consequence, a series of studies were per-
formed with hypo-osmolar ORS formulations comparing glu-
cose and food-based compositions. These studies
established the efficacy of hypo-osmolar, glucose-based
formulations (without the presence of food polymers),
which represented yet another milestone in the improve-
ment of ORS [27•]. Since then, several governments in
Asia and Africa have adopted the use of reduced osmolarity
(or hypo-osmlar) ORS formulation as the standard ORS treat-
ment for diarrhea [28].
Despite the ready demonstration that employment of ORS
during episodes of acute diarrhea improves morbidity and
mortality especially in young children, the actual usage of
ORS has varied markedly over the past 30 years for many
reasons, and remained relatively low and unchanged in many
countries [29]. Early on, there were extensive media events
promoting employment of ORS during episodes of acute
diarrhea. These campaigns have been judged effective to
increase ORS uptake, but have usually been intermittent in
duration. Further, such efforts have frequently been supersed-
ed by maternal education programs that have focused on
providing education addressing the totality of child welfare,
with emphasis on breast feeding, vaccination programs, and
other important health, nutrition, and hygiene issues for chil-
dren, in addition to the employment of ORS, with consequent
loss of focus on the latter. To maintain continued high levels of
ORS, it is necessary to ensure continual media education. This
need for continued and sustained education is critical, if only
to provide sustained education of ORS for the women who
become newmothers every year. Though deaths from diarrhea
are decreasing, it is important to emphasize that acute diarrhea
remains the second highest cause of mortality in children
under the age of 5 in developing countries (and only slightly
less than that of pneumonia) [30].
UNICEF/WHO released an important monograph in 2009
entitledDiarrhoea:Why children are still dying and What can
be done? [31] Data presented in this publication emphasized
that overall use of ORS by mothers in developing countries
was only approximately 33 % (Fig. 2). This figure is far too
low and certainly may be an important factor why children are
still dying from episodes of acute diarrhea. An adequate
explanation for this overall low use of ORS in the treatment
of acute diarrhea is not totally known. In addition to cultural
and access issues, an important issue is that ORS is not a drug
(and hence at risk of not being perceived as a medicine of real
value), nor is it expensive, and therefore may be considered as
not as effective as treatments that are expensive and must be
purchased from pharmacies (e.g., antibiotics). Though all hese
reasons are distinct possibilities, we believe that a major
contributing factor for ORS not being widely employed is its
inability to reduce stool output dramatically. That is, mothers
are most interested in relief of their child’s symptoms, i.e.,
reduction in diarrhea, and are not necessarily concerned about
correction of acute dehydration and metabolic acidosis.
Thus, can ORS be improved so that its use will result in a
substantial reduction in stool output, i.e., symptomatic relief
of a child’s acute diarrhea? Since the small intestine is the site
in which glucose stimulates active Na and fluid absorption
(and glucose does not stimulate fluid and Na absorption in the
colon), in 1993 we posed the question as to whether a new
formulation could be developed that, in addition to using the
small intestine, would also enhance Na and fluid absorption in
the large intestine? Several observations make this therapeutic
approach a very attractive concept; they emphasized the po-
tential role of short-chain fatty acids (SCFA) and have been
the focus of our studies for the past two decades [32, 33••,
34••, 35–37].
Short-Chain Fatty Acids (SCFA)
Interest in SCFA began approximately 30 years ago [38].
Studies at that time demonstrated that SCFA (primarily ace-
tate, propionate, and butyrate) are the primary stool anion but
are not present in the diet. These SCFA are synthesized (i.e.,
fermented) by colonic bacteria from non-absorbed carbohy-
drates (Fig. 3). Carbohydrates are not absorbed in the colon
and small soluble carbohydrates induce fluid secretion on an
osmotic basis; in contrast, SCFA are rapidly absorbed in the
colon and stimulate fluid and Na absorption [39]. As a con-
sequence, the production of SCFA represents an adaptive
mechanism by which the colon conserves carbohydrate, cal-
ories, fluid, and electrolytes.
Studies were performed to identify the cellular mechanism
by which SCFA are absorbed and stimulate Na absorption.
These in vitro studies established a mechanism for butyrate
absorption that is linked to both Na and Cl absorption [31, 40].
This model proposed that the uptake of butyrate across the
apical membrane is a result of a butyrate–bicarbonate
Fig. 2 Percent of children under 5 with diarrhea receiving at least one
ORS packet during illness, by region, 2005–2008. Adapted from the
UNICEF-WHO publication, Children are still dying from acute diarrhea;
What can be done? (2009) [29]
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exchange that in turn is linked to a Cl–bicarbonate anion
exchange and a Na–H exchange (NHE). To confirm the role
of a Na–H exchange, additional experiments were performed
in which Na was removed and 1 mM amiloride (which in-
hibits NHE3 function) was added, both of which inhibited
butyrate-stimulation of Na absorption [31, 32]. As NHE3 is an
apical Na–H exchange that is inhibited by cyclic AMP, the
effect of cyclic AMP to alter butyrate-stimulation of Na ab-
sorption was also tested and surprisingly failed to alter Na
absorption. Thus, in vitro butyrate stimulated Na absorption
via a cyclic AMP-independent mechanism [32]. At approxi-
mately the same time, studies performed by B.S. Ramakrishna
et al. in the in vivo ileum and colon established that SCFA
stimulation of Na absorption was not altered by cholera toxin
[33••]. Such an observation suggested that SCFA stimulated
Na absorption via a cyclic AMP-independent process. As a
consequence, these observations suggested that SCFA in the
colon might function similar to glucose in the small intestine
to enhance fluid and Na absorption during an acute diarrheal
illness in which an enterotoxin, e.g., cholera enterotoxin or
E. coli enterotoxins, has induced substantial losses of fluid and
electrolytes via stimulation of active Cl/HCO3 secretion (and
inhibition of Na–H exchange).
Resistant Starch: A Delivery Mechanism for SCFA
Production
How best to deliver SCFA to the colon represented a chal-
lenge. Feeding SCFAwas not a possibility, as transport mech-
anisms had been identified in the small intestine for SCFA
absorption [41, 42]. Thus, oral administration of SCFAwould
not result in the delivery of SCFA to the colon. Graeme Young
suggested that use of resistant starch (RS), i.e., starch that was
relatively resistant to amylase digestion in the small intestine
[43], represented a potential approach to provide substrate for
local intracolonic production of SCFA, as feeding of resistant
starch to normal subjects had been shown to increase fecal
butyrate excretion [44]. As a consequence, the initial critical
experiment was to determine whether RS incubated in vitro
with stool from patients with acute cholera would result in
SCFA production [45]. Such in vitro experiments established
that such stool (despite use of antibiotics in the treatment of
cholera) possessed the ability to ferment RS with the produc-
tion of SCFA including butyrate. This latter observation led to
the initiation of three randomized, double-blind clinical trials
that were performed at Christian Medical College (CMC)-
Vellore in South India [46••, 47•, 48••].
Clinical Trials with RS-ORS
These studies compared a specific RS (high-amylose maize
starch, referred to as HAMS), hence HAMS–ORS, in two
trials in adults with acute cholera and one in children with
non-cholera diarrhea [46••, 47•, 48••]. One of the adult studies
and the clinical trial in children used an iso-osmolar HAMS-
ORS formulation, while the other adult study employed a
hypo-osmolar HAMS-ORS formulation (Fig. 4). In all three
studies, the HAMS-ORS formulation was associated with a
30–50 % reduction in time to the first formed stool—which
represents a very significant reduction in stool output.
Fig. 3 Importance of colonic microbiota in the production of short-chain
fatty acids (SCFA) in the large intestine. a Carbohydrates that are not
absorbed in the small intestine enter the colonwhere they are fermented to
SCFAwhich are absorbed and stimulate Na and fluid absorption. SCFA
production represents an adaptive process to conserve calories, Na and
water. b Following antibiotic administration, there is a reduction in SCFA
production often resulting in diarrhea as the non-absorbed carbohydrates
induce fluid secretion via an osmotic mechanism. Much attention has
focused on C. difficile in the genesis of antibiotic-associated diarrhea, but
this represents no more than 20 % of all antibiotic-associated diarrhea,
and evidence indicates that suppression of SCFA production likely is
responsible for the majority of antibiotic-associated diarrhea
Fig. 4 Time to the first formed stool. Results of a randomized, double-
blind clinical trial in adults with acute cholera randomized to hypo-
osmolar ORS or HAMS-hypo-osmolar ORS (shown here as resistant
starch) [46••]. The resistant starch group had a 55 % reduction in time
to first formed stool as well as reduction in stool output
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Figure 5 summarizes the changes in small and large intes-
tinal fluid movement in health (panel a), in patients with
cholera (panel b) and then treated either with ORS (panel c)
or with RS-ORS (panel d). Additional details are provided in
the legend of Fig. 5.
Toward Identification of the Optimal RS-ORS
These observations raised the important question whether
HAMS-ORS would represent the ideal or optimal ORS to
develop for world-wide adaption as the most efficacy ORS
formulation. The answer to that query has not been resolved as
yet, but preliminary studies suggest that other modified
starches, especially those that qualify as resistant starch, might
be equally or more efficacious. To address this possibility two
linked experiments were designed: the initial one was an
in vitro study in which 75 different compounds that had the
potential for catabolism to yield SCFA were individually
incubated with normal stool (unpublished observations). As
some of these compounds were not starches, the term used to
describe these compounds was fermentable substances (FS)
or non-digestible carbohydrates. Six of these FS that yielded
the highest concentration of SCFA during in vitro incubation
with human stool were selected for in vivo studies in the rat
using a newly developed experimental approach—a whole
gut perfusion [49]. This experimental design was devised to
reproduce acute diarrhea in humans by administering either
enterotoxins ofCholera vibrio or E. coli to the rodent intestine
that had been cannulated proximally at the pylorus and distally
at the rectum. As a consequence, this experimental design
permitted determination of fluid movement in the entire small
and large intestine during perfusion with different electrolyte
solutions. The results of these studies demonstrated that
HAMS-ORS resulted in greater fluid absorption in the pres-
ence of cholera enterotoxin than the present standard ORS
formulation—glucose–hypo-osmolar ORS. However, these
experiments also revealed that two modified HAMS com-
pounds (esterified starches containing varying amounts of
acetyl groups) resulted in even higher rates of fluid absorption
during cholera toxin-induced fluid secretion (unpublished
observations).
In order to proceed to clinical trials with these esterified
starches another problem required attention. Most of these
starches when added to a glucose–electrolyte solution did
not yield a clear solution but rather had an opaque appearance
that, over a short period of time, often just 1 h, would settle out
of suspension. As a result, efforts were required to identify
one or more suspending agents that would ensure that,
even without stirring, a child would receive the desired
amount. These ORS formulations containing an anti-
settling agent were also studied in the in vivo whole gut
perfusion system. These studies demonstrated that there
was no loss of the advantages provided by the esterified
HAMS solutions with varying amounts of acetylation
compared to the HAMS-ORS formulation (unpublished
Fig. 5 Model of intestinal fluid movement in health and in acute cholera
treated with ORS. (Width of arrows provides approximation of fluid
movement; values presented are per 24 h.) a In health, the major fraction
of fluid entering the small intestine is absorbed with approximately 2 l
reaching the colon where all but less than 200 ml is also absorbed.b In
cholera, there is significant small intestinal fluid secretion secondary to
active Cl secretion and inhibition of NaCl absorption (see Fig. 1) resulting
in enhanced ileo-cecal flow; in addition, colonic Na-Cl and fluid absorp-
tion is reduced resulting in up to 7 l of diarrhea per day. c Administration
of ORS does not alter active Cl secretion but enhances fluid absorption by
stimulating active Na absorption (via a cAMP-independent process) in
the small intestine correcting dehydration but only modestly reducing
ileo-cecal flow. Colonic fluid absorption is not altered. d Administration
of HAMS (a resistant starch)-ORS results in identical changes in the small
intestine but in the colon HAMS is fermented to SCFA that stimulates Na
absorption (also via a cAMP-independent process) resulting in further
rehydration and a substantial reduction in diarrhea
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observations). As a consequence, clinical trials have been
designed and recently started to determine which of these
three HAMS-related ORS formulations each containing a
suspending agent will result in greater efficacy in the treatment
of acute diarrhea in adults. Such a compound will then be
selected for more detailed studies including safety, efficacy in
both adults and children, and, most importantly, in different
areas of the developing world to establish its efficacy with
several different pathogenic agents.
Role of Zinc in ORS Therapy
Table 1 lists the composition of the present WHO-UNICEF
recommended treatment for acute diarrhea. In addition to
using a glucose–hypo-osmolar ORS formulation for rehydra-
tion, present guidelines also indicate that a 10-day course of
Zn should be administered. This recommendation is based on
several observations that demonstrated that Zn supplementa-
tion resulted in a 12–25 % reduction in acute diarrhea in
children [50]. Total body stores of Zn in humans are normally
quite low and diarrhea results in Zn losses. However, it has not
been unequivocally established whether Zn supplementation
in acute diarrhea is efficacious only in Zn-deficient children or
in both Zn-deficient and Zn-surfeit children. If Zn treatment
reduces diarrhea only in Zn-deficient children, then the mech-
anism of Zn’s action would likely represent correction of a Zn
micro-nutrient deficiency. In support of this possibility are
experimental observations that small intestinal function is
abnormal in Zn-deficiency and that intestinal fluid secretion
is both enhanced in Zn-deficiency and corrected by Zn ad-
ministration [51, 52]. In contrast, if Zn treatment of diarrhea is
also effective in Zn-surfeit children (as well as in Zn-deficient
children), correction of a Zn micro-nutrient deficiency would
not be an adequate explanation for both observations. It would
then be necessary to postulate that Zn would also be effica-
cious as an anti-diarrheal agent, i.e., that Zn could enhance
fluid and Na absorption and/or inhibition fluid and Cl secre-
tion. Indeed, recent studies have demonstrated that Zn can
enhance Na absorption via virtue of stimulation of NHE3
function [53] and can inhibit cyclic AMP-induced Cl secretion
by functioning as a basolateral K channel blocker [54].
Conclusions
Oral rehydration therapy (ORT) has been developed over the
past 40 years and has been established as the standard of
therapy for the treatment of the dehydration and metabolic
acidosis associated with acute diarrhea. The use of ORS has
been attributed as the primary reason for the substantial re-
duction in morbidity and mortality of acute infectious diar-
rhea. Despite these successes, ORS is not employed by
mothers to the extent that one would anticipate, and multiple
efforts have been made to improve the formulation of ORS.
This review describes our efforts to establish the incorporation
of a fermentable (or resistant) starch into ORS based on (1) the
delivery of such a fermentable starch to the colon where
fermentation to SCFA occurs, and (2) SCFA stimulation of
colonic Na absorption via a cyclic AMP-independent mecha-
nism. As a result, these newly formulated ORS that are pres-
ently being studied in clinical trials represent a “dual-action”
ORS in which Na and fluid absorption is enhanced in both
small and large intestine.
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